AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29045207
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of tofacitinib administered orally twice daily
Trial: 29045207
Drug: Placebo (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (with a switch to 5 mg of tofacitinib at 3 months)
Trial: 22990950
Drug: Multimodal shoulder
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal shoulder injection
Trial: 21899843
Drug: Atorvastatin or
RxNorm normalized name: atorvastatin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin or pitavastatin treatment
Trial: 16481597
Drug: Creatine 10
RxNorm normalized name: creatine 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine 10 g/day
Trial: 12762352
Drug: Chlorine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorine inhalation (1.0 parts per million for 15 min)
Trial: 8151150
Drug: Aciclovir granules
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aciclovir granules (40% w/w aciclovir) at a dose of 20 mg/kg four times daily for five to seven days
Trial: 8151150
Drug: Conventional symptomatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional symptomatic therapy
Trial: 31916648
Drug: quadruple‐therapy with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quadruple‐therapy with 2 g/day N. sativa
Trial: 31916648
Drug: quadruple‐therapy with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quadruple‐therapy with 2 g/day placebo
Trial: 30173153
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) with Methotrexate (MTX) 20 mg/week
Trial: 30173153
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) with Methotrexate (MTX) 7.5 mg/week
Trial: 23368897
Drug: Fluticasone/formoterol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol combination therapy (100/10 μg b.i.d. or 250/10 μg b.i.d.)
Trial: 23368897
Drug: Fluticasone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone + formoterol (100 μg + 12 μg b.i.d. or 250 μg + 12 μg b.i.d.)
Trial: 23368897
Drug: Fluticasone/formoterol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol combination therapy
Trial: 11323554
Drug: Creatine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (20 g.d‐1 for 5 days)
Trial: 9195406
Drug: Interferon-alpha therapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha therapy (6-9 MU; six times weekly for 2 weeks followed by thrice weekly for 22 additional weeks)
Trial: 8186869
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy (20 Gy in four 5 Gy fractions)
Trial: 8186869
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy (20 Gy) plus local microwave hyperthermia
Trial: 8186869
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with hyperthermia
Trial: 25523718
Drug: High-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose trivalent inactivated influenza vaccine (TIV) - 60 μg
Trial: 25523718
Drug: Standard-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose trivalent inactivated influenza vaccine (TIV) - 15 μg
Trial: 14982697
Drug: Mecamylamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (10 mg oral)
Trial: 11420874
Drug: Daily hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hemodialysis (DHD = 6 x 2 h/week)
Trial: 8073910
Drug: Thymoxamine (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoxamine (alpha adrenergic receptor antagonist)
Trial: 8073910
Drug: Methoxamine (alpha-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxamine (alpha-1 adrenergic receptor agonist)
Trial: 2673620
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion (0.07 mg/kg/min)
Trial: 2673620
Drug: Nicotine during
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine during adenosine infusion
Trial: 2673620
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of nicotine and adenosine
Trial: 17250777
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg imipramine
Trial: 11210404
Drug: Azithromycin 1200
RxNorm normalized name: azithromycin 1200 MG per 30 ML Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1200 mg/day (changed to 600 mg/day) for Days 8 to 21 with zidovudine 100 mg, five times/day.
Trial: 11210404
Drug: Azithromycin 1200
RxNorm normalized name: azithromycin 1200 MG per 30 ML Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1200 mg/day for Days 8 to 21 with dideoxyinosine 200 mg twice daily.
Trial: 11210404
Drug: Placebo equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo equivalent to azithromycin for Days 8 to 21 with dideoxyinosine 200 mg twice daily.
Trial: 1981014
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with estrogenic recruitment (low doses of diethylstilbesterol)
Trial: 25304836
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose antibiotic regimen (n = 103)
Trial: 25304836
Drug: Multidose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidose antibiotic regimen (n = 102)
Trial: 25359150
Drug: Pateclizumab 360
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pateclizumab 360 mg
Trial: 20413058
Drug: Once-daily ADPREM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily ADPREM
Trial: 20413058
Drug: Twice-daily CRM
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily CRM
Trial: 8621019
Drug: Vanadyl sulfate
RxNorm normalized name: Vanadyl Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanadyl sulfate (100 mg/day)
Trial: 1591738
Drug: Nimodipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (40 mg)
Trial: 6389273
Drug: Antacid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid group A (7.5 ml, 103.5 mmol antacid/day)
Trial: 6389273
Drug: Antacid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid group B (15 ml, 207 mmol antacid/day)
Trial: 6389273
Drug: Antacid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid group C (30 ml, 414 mmol antacid/day)
Trial: 6389273
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (15 ml)
Trial: 23380429
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg meloxicam orodispersible tablet (ODT)
Trial: 3777684
Drug: Catecholamine infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Catecholamine infusion (dopamine or dobutamine, Group III, n = 17)
Trial: 26925704
Drug: Sativex (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sativex (up to 108 mg THC/100 mg CBD)
Trial: 26925704
Drug: Self-titrated doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-titrated doses of Sativex
Trial: 24077196
Drug: Lateral parasagittal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral parasagittal interlaminar epidural steroid injection (PIL)
Trial: 24077196
Drug: Midline interlaminar
RxNorm normalized name: amidoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midline interlaminar epidural steroid injection (MIL)
Trial: 20509997
Drug: Adefovir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir (10 mg once daily for 48 weeks)
Trial: 12682421
Drug: alpha-tocopherol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-tocopherol (400 IU dL-a-tocopherol daily)
Trial: 9010746
Drug: Estradiol-releasing vaginal
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol-releasing vaginal ring (2 mg/3 months) and oral progestin for 7 days every month
Trial: 9010746
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (50 micrograms/day) with a levonorgestrel-releasing IUD (20 micrograms/day)
Trial: 1446959
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (R)
Trial: 3792350
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide and 5 mg amiloride hydrochloride (combination therapy)
Trial: 3792350
Drug: Diuretics (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (50 mg hydrochlorothiazide and 5 mg amiloride hydrochloride)
Trial: 19249923
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (PCA) with fentanyl 0.5 microg/kg every 15 minutes (maximum 4 doses/hour)
Trial: 19249923
Drug: PRN intravenous
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN intravenous fentanyl 25-50 microg every 30 minutes
Trial: 16441618
Drug: Alginate gel
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate gel Flaminal (test)
Trial: 16441618
Drug: Hydrocolloid gel
RxNorm normalized name: Band-Aid Hydro Seal Hydrocolloid Gel Bandages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid gel Intrasite (control)
Trial: 10886120
Drug: GR205171 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR205171 25 mg i.v. + ondansetron 8 mg i.v.
Trial: 10886120
Drug: Hyoscine hydrobromide
RxNorm normalized name: Hyoscine hydrobromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine hydrobromide 0.6 mg orally (positive control)
Trial: 9082268
Drug: Warm anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm anesthetic solution (37 degrees C)
Trial: 9082268
Drug: Cold anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold anesthetic solution (20 degrees C)
Trial: 8452165
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily for 10 days
Trial: 8452165
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice daily for 10 days
Trial: 3512783
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without bleomycin
Trial: 3512783
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy with immunotherapy (BCG, levamisole, or both)
Trial: 3512783
Drug: Initial full-dose
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial full-dose therapy for patients aged 65 or older
Trial: 3512783
Drug: Initial dose
RxNorm normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose reduction of 50% for patients aged 65 or older
Trial: 27716478
Drug: Panitumumab 6
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 6 mg/kg once every 2 weeks
Trial: 27716478
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m2 followed by 250 mg/m2 weekly)
Trial: 21660669
Drug: Bright white
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white light (BWL) treatment for 30 min every morning during chemotherapy
Trial: 21660669
Drug: Dim red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red light (DRL) treatment for 30 min every morning during chemotherapy
Trial: 12379063
Drug: Rifampin and
RxNorm normalized name: Rifampin and Isoniazid Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin and pyrazinamide daily for 2 months (n = 307)
Trial: 12379063
Drug: Isoniazid daily
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid daily for 6 months (n = 282)
Trial: 1850142
Drug: Flumazenil 200
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil 200 mg
Trial: 1850142
Drug: Flumazenil 600
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil 600 mg
Trial: 6130073
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of buspirone
Trial: 6130073
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of diazepam
Trial: 6130073
Drug: Alcohol (0.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.85 g/kg for men; 0.72 g/kg for women)
Trial: 31420063
Drug: Featback (automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Featback (automated feedback on a short monitoring questionnaire weekly)
Trial: 31420063
Drug: Featback with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Featback with weekly e‐mail or chat support from an expert patient
Trial: 31420063
Drug: Weekly support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly support from an expert patient
Trial: 23080350
Drug: Subfascial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subfascial injection of 30 mL of ropivacaine 0.5%
Trial: 23080350
Drug: Extrafascial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafascial injection of 30 mL of ropivacaine 0.5%
Trial: 16950429
Drug: Propionyl‐L‐carnitine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl‐L‐carnitine (6 g/day)
Trial: 15568141
Drug: Ethanol 0.73
RxNorm normalized name: ethanol 0.73 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.73 g/kg, 1 h before isoniazid, followed by 0.11 g/kg ethanol orally every hour thereafter for 7 h
Trial: 9209670
Drug: Intrapleural combination
RxNorm normalized name: INTRAPLEURAL MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural combination of DDP (60 mg/m2) and CBDCA (270 mg/m2)
Trial: 9209670
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous DDP treatment
Trial: 9209670
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of CBDCA alone
Trial: 30293364
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with narrow-spectrum intense pulsed light and fractional carbon dioxide laser
Trial: 24169248
Drug: LMA I-gel
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMA I-gel
Trial: 21394052
Drug: 0.5‐mg ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐mg ranibizumab
Trial: 21394052
Drug: 4‐mg triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐mg triamcinolone
Trial: 18329580
Drug: Active low-level
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active low-level laser therapy (LLLT) (Helium Neon, 632.8 nm, 30 mW)
Trial: 18329580
Drug: Sham low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham low-level laser therapy (placebo)
Trial: 14747424
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral dose of imatinib (capsule)
Trial: 14747424
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral dose of imatinib (oral solution)
Trial: 14747424
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg i.v. infusion of imatinib
Trial: 8283896
Drug: Algorithm therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm therapy based on on-site coagulation monitoring
Trial: 2660970
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections for 1 year
Trial: 5343357
Drug: L-DOPA (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (high oral dosage)
Trial: 24051437
Drug: ERAP (cell‐permeable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERAP (cell‐permeable peptide inhibitor)
Trial: 24051437
Drug: Tamoxifen (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (standard treatment)
Trial: 21536689
Drug: Computer-assisted therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted therapies
Trial: 21536689
Drug: Weaker comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weaker comparison conditions (e.g., wait-list controls)
Trial: 15291859
Drug: Early and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early and high-dose epirubicin (360 mg, 12 instillations)
Trial: 15291859
Drug: Delayed and
RxNorm normalized name: TABLET, DELAYED AND EXTENDED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed and high-dose epirubicin (360 mg, 12 instillations)
Trial: 15291859
Drug: Delayed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delayed low-dose epirubicin (180 mg, 30 mg once every 2 weeks, six times)
Trial: 15291859
Drug: Early low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early low-dose epirubicin (180 mg, three instillations before 7 days after TURBT)
Trial: 11256987
Drug: Inhaled terbutaline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline, 0.5 mg three times daily for 2 weeks
Trial: 11256987
Drug: Inhaled budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide, 400 microg twice daily for 2 weeks
Trial: 9048145
Drug: Enhanced methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced methadone treatment
Trial: 29196825
Drug: FORTA-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FORTA-guided treatment
Trial: 29196825
Drug: Standard geriatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard geriatric treatment
Trial: 11929419
Drug: Decongestants (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestants (topical or oral)
Trial: 11929419
Drug: Unknown medication
RxNorm normalized name: Fe heme polypeptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unknown medication
Trial: 1888325
Drug: Treatment effectiveness
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effectiveness
Trial: 9466525
Drug: Investigational vaccines
RxNorm normalized name: INVESTIGATIONAL VACCINES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational vaccines (three types)
Trial: 1803847
Drug: Active buffering
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active buffering lozenge (Profylin)
Trial: 1803847
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge (not buffered)
Trial: 1803847
Drug: Active buffering
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active buffering lozenge (Profylin) after sucrose rinse
Trial: 1803847
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge after sucrose rinse
Trial: 31119846
Drug: TRK‐100STP 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRK‐100STP 120 μg
Trial: 28273240
Drug: Laser pan-retinal
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser pan-retinal photocoagulation with intravitreal bevacizumab injections
Trial: 26649465
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural therapy (ICBT) with therapist support for 10 weeks
Trial: 12476542
Drug: Desloratadine/pseudoephedrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine/pseudoephedrine (5 mg/240 mg)
Trial: 12476542
Drug: Pseudoephedrine (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine (240 mg)
Trial: 9761434
Drug: UFT (Tegafur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (Tegafur and Uracil) administered post-operatively to 98 patients